California is currently home to 5618 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
Recruiting
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Retina-Vitreous Associates Medical Group, Beverly Hills, California
Conditions: Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
A First-in-Human Single and Multiple Ascending Dose Study of MT-501
Recruiting
First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) with Single and Multiple Ascending Oral Doses of MT-501 in Healthy Adults.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
06/13/2025
Locations: Mirador Clinical Department, San Diego, California
Conditions: Healthy Volunteers
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
Recruiting
This phase I trial tests the safety and side effects of zanubrutinib in combination with odronextamab and how well it works in treating patients with Richter's transformation. Zanubrutinib, a tyrosine kinase inhibitor, blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. Odronextamab is a bispecific monoclonal antibody that can bind to two different antigens at the same time. Odronextamab binds to CD20 found on B-cells (a type of white blood cell)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Recruiting
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effec... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: UCLA, Los Angeles, California
Conditions: Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer
A Study of MGC028 in Participants With Advanced Solid Tumors
Recruiting
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: UCSF - Helen Diller Family Cancer Center, San Francisco, California
Conditions: Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
Recruiting
The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and 2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.
Gender:
ALL
Ages:
3 months and below
Trial Updated:
06/13/2025
Locations: Children's Hospital of Orange County, Orange, California
Conditions: Post-ligation Cardiac Syndrome
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease
Recruiting
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2025
Locations: GSK Investigational Site, Los Angeles, California
Conditions: Liver Diseases, Alcoholic
Early Detection of Advanced Adenomas and Colorectal Cancer
Recruiting
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: City of Hope Medical Center, Monrovia, California
Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma, Colorectal Disorders, Colorectal Dysplasia, Colorectal Cancer Stage I, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Stage IV, Colorectal Neoplasms Malignant, Colorectal Serrated Adenocarcinoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Adenoma With Mild Dysplasia, Colorectal Adenoma With Moderate Dysplasia, Colorectal Adenoma and Carcinoma 1, Colorectal Adenomatous Polyp, Colorectal Adenocarcinoma Metastatic in the Liver
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
Recruiting
This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM). The study duration will be approximately 92 weeks for all participants. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either empasiprubart or placebo, respectively, during the treatment period (duration of 25 weeks). At the end of the treatment period, all the participants will enter a safety follow-up period (d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Profound Research LLC, Oceanside, California
Conditions: Dermatomyositis, Myositis
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Recruiting
This phase I trial tests the safety, side effects, and best dose of carfilzomib in combination with sotorasib in treating patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Carfilzomib is a drug that binds to and inhibits the activity of the protein complex th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Recruiting
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransfe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: University of California Los Angeles, Los Angeles, California
Conditions: MTAP-deleted Solid Tumors
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
Recruiting
The objective of the study is to assess the safety and technical feasibility of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
Gender:
ALL
Ages:
Between 22 years and 90 years
Trial Updated:
06/13/2025
Locations: Kaiser Permanente, San Francisco, California
Conditions: Tricuspid Regurgitation